Nautilus Biotechnology Stock Current Valuation
| NAUT Stock | USD 2.40 0.02 0.84% |
Valuation analysis of Nautilus Biotechnology helps investors to measure Nautilus Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -5.49 in 2024. Enterprise Value Multiple is likely to drop to -5.49 in 2024. Fundamental drivers impacting Nautilus Biotechnology's valuation include:
Price Book 1.3487 | Enterprise Value 192.3 M | Enterprise Value Ebitda (2.00) |
Undervalued
Today
Please note that Nautilus Biotechnology's price fluctuation is risky at this time. Calculation of the real value of Nautilus Biotechnology is based on 3 months time horizon. Increasing Nautilus Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nautilus Biotechnology's intrinsic value may or may not be the same as its current market price of 2.40, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.4 | Real 2.98 | Target 5.0 | Hype 2.41 | Naive 2.39 |
The intrinsic value of Nautilus Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nautilus Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nautilus Biotechnology helps investors to forecast how Nautilus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nautilus Biotechnology more accurately as focusing exclusively on Nautilus Biotechnology's fundamentals will not take into account other important factors: Nautilus Biotechnology Company Current Valuation Analysis
Nautilus Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nautilus Biotechnology Current Valuation | 192.31 M |
Most of Nautilus Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nautilus Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nautilus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Nautilus Biotechnology is extremely important. It helps to project a fair market value of Nautilus Stock properly, considering its historical fundamentals such as Current Valuation. Since Nautilus Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nautilus Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nautilus Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nautilus Biotechnology has a Current Valuation of 192.31 M. This is 98.66% lower than that of the Biotechnology sector and 95.86% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.84% higher than that of the company.
Nautilus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nautilus Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics of similar companies.Nautilus Biotechnology is currently under evaluation in current valuation category among its peers.
Nautilus Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nautilus Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nautilus Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Nautilus Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 192.31 M | ||||
| Shares Outstanding | 125.56 M | ||||
| Shares Owned By Insiders | 33.46 % | ||||
| Shares Owned By Institutions | 50.22 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Book | 1.35 X | ||||
| EBITDA | (74.3 M) | ||||
| Net Income | (63.67 M) | ||||
| Cash And Equivalents | 299.34 M | ||||
| Cash Per Share | 2.40 X | ||||
| Total Debt | 34.63 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 49.75 X | ||||
| Book Value Per Share | 1.78 X | ||||
| Cash Flow From Operations | (51.71 M) | ||||
| Short Ratio | 19.69 X | ||||
| Earnings Per Share | (0.56) X | ||||
| Target Price | 3.56 | ||||
| Number Of Employees | 161 | ||||
| Beta | 1.04 | ||||
| Market Capitalization | 301.35 M | ||||
| Total Asset | 305.56 M | ||||
| Retained Earnings | (202.24 M) | ||||
| Working Capital | 167.72 M | ||||
| Net Asset | 305.56 M |
About Nautilus Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.